Ratings for 10x Genomics TXG were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 4 | 0 | 1 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 1 | 3 | 0 | 1 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $39.0, a high estimate of $55.00, and a low estimate of $24.00. A decline of 26.94% from the prior average price target is evident in the current average.
Decoding Analyst Ratings: A Detailed Look
The standing of 10x Genomics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tycho Peterson | Jefferies | Announces | Hold | $24.00 | - |
| Dan Leonard | UBS | Lowers | Neutral | $30.00 | $52.00 |
| Derik De Bruin | B of A Securities | Lowers | Neutral | $36.00 | $45.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Sell | $26.00 | $30.00 |
| Dan Brennan | TD Cowen | Lowers | Hold | $32.00 | $57.00 |
| Daniel Arias | Stifel | Lowers | Buy | $53.00 | $63.00 |
| Kyle Mikson | Canaccord Genuity | Lowers | Buy | $50.00 | $65.00 |
| Justin Bowers | Deutsche Bank | Lowers | Buy | $55.00 | $60.00 |
| Luke Sergott | Barclays | Lowers | Overweight | $45.00 | $55.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to 10x Genomics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 10x Genomics compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for 10x Genomics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into 10x Genomics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on 10x Genomics analyst ratings.
Discovering 10x Genomics: A Closer Look
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
10x Genomics: A Financial Overview
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: 10x Genomics displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 5.0%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: 10x Genomics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -42.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): 10x Genomics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -8.21%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): 10x Genomics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.35%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.13.
The Significance of Analyst Ratings Explained
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
